Yüklüyor......
Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer
Pembrolizumab, or anti-programmed death receptor 1 antibody, is an immune checkpoint inhibitor that can cause immune-related adverse events. We herein report for the first time the progression of hypopituitarism and hypothyroidism after treatment with pembrolizumab in a patient with adrenal metastas...
Kaydedildi:
| Yayımlandı: | Intern Med |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
The Japanese Society of Internal Medicine
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6949454/ https://ncbi.nlm.nih.gov/pubmed/31462588 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.3008-19 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|